Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Inclusion Criteria:

* Age more than 18 years old, regardless of gender;
* SCLC diagnosis based on histopathology according to the Primary Lung Cancer Diagnosis and Treatment Guidelines (2018 edition);
* TNM stage II-IV;
* ECOG PS score ≤2;
* Predicted survival time more than 3 months;
* Provision of signed informed consent.

Exclusion Criteria:

* Previous interventional therapies such as iodine seed implantation (within the past six months), ablation, BACE, or immunotherapy;
* Concurrent presence of other incurable malignant tumors;
* White blood cell count less than 3×10\^9/L, neutrophil absolute count less than 1.5×10\^9/L, neutrophil/lymphocyte ratio equal to or greater than 3, platelet count less than 50×10\^9/L, hemoglobin concentration less than 90 g/L;
* Hepatic and renal insufficiency (creatinine level exceeding 176.8μmol/L); Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels more than twice the upper limit of normal;
* Uncorrectable coagulopathy or concurrent active hemoptysis;
* Complicated with active infection requiring antibiotic treatment;
* Uncontrolled hypertension, diabetes, or cardiovascular disease;
* Allergy to contrast agents;
* Women who are pregnant or lactating.